abrdn Life Sciences Investors
HQL
75 hedge funds and large institutions have $136M invested in abrdn Life Sciences Investors in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 10 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 26
8% more capital invested
Capital invested by funds: $126M → $136M (+$10.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 35.25% → 35.17% (-0.09%)
5% less funds holding
Funds holding: 79 → 75 (-4)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$13.1M |
| 2 |
SIA
Sit Investment Associates
Minneapolis,
Minnesota
|
+$2.61M |
| 3 |
AW
Atlas Wealth
Cincinnati,
Ohio
|
+$1.13M |
| 4 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$796K |
| 5 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$416K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
-$2.51M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$1.15M |
| 3 |
RL
RPO LLC
Stamford,
Connecticut
|
-$1.07M |
| 4 |
1CP
1607 Capital Partners
Richmond,
Virginia
|
-$840K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$827K |
HQL Hedge Fund Activity: Q2 2024 in Review
75 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2024, worth a combined $136M — up 8.3% from $126M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HQL and 8 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 32 added.
The largest buyer was Saba Capital Management, adding an estimated $13.1M. The largest seller was Lazard Asset Management, exiting entirely with an estimated $2.51M sold.
- 75 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2024, down from 79 in Q1 2024.
- Funds reported $136M of abrdn Life Sciences Investors stock for Q2 2024, up 8.3% quarter-over-quarter.
- 8 funds opened new abrdn Life Sciences Investors positions in Q2 2024 and 10 closed out, a net change of -2 holders.
- The largest abrdn Life Sciences Investors buyer in Q2 2024 was Saba Capital Management, an estimated $13.1M added.
- The largest abrdn Life Sciences Investors seller in Q2 2024 was Lazard Asset Management, an estimated $2.51M sold.
Based on aggregated 13F filings for Q2 2024.